TY  - GEN
AU  - Alatrash,Gheath
AU  - de Lima,Marcos
AU  - Hamerschlak,Nelson
AU  - Pelosini,Matteo
AU  - Wang,Xuemei
AU  - Xiao,Lianchun
AU  - Kerbauy,Fabio
AU  - Chiattone,Alexandre
AU  - Rondon,Gabriela
AU  - Qazilbash,Muzaffar H
AU  - Giralt,Sergio A
AU  - de Padua Silva,Leandro
AU  - Hosing,Chitra
AU  - Kebriaei,Partow
AU  - Zhang,Weiqing
AU  - Nieto,Yago
AU  - Saliba,Rima M
AU  - Champlin,Richard E
AU  - Andersson,Borje S
TI  - Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life
SN  - 1523-6536
PY  - 2012///0220
KW  - Acute Disease
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - administration & dosage
KW  - Busulfan
KW  - Disease-Free Survival
KW  - Female
KW  - Follow-Up Studies
KW  - Graft vs Host Disease
KW  - mortality
KW  - Hematopoietic Stem Cell Transplantation
KW  - Humans
KW  - Leukemia, Myeloid, Acute
KW  - Male
KW  - Middle Aged
KW  - Myelodysplastic Syndromes
KW  - Prospective Studies
KW  - Survival Rate
KW  - Transplantation Conditioning
KW  - Transplantation, Homologous
KW  - Vidarabine
N1  - Publication Type: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/j.bbmt.2011.02.007
ER  -